Výsledky vyhledávání - "Alison K. Cardenas"

Supplementary Table S4. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Autor: José Baselga, Jerry Y. Hsu, Michael C. Wei, Thomas J. Stout, Timothy R. Wilson, Na Cui, Alison K. Cardenas, Mafalda Oliveira, Lajos Pusztai, Manish R. Patel, Philippe L. Bedard, Andrés Cervantes, Ian E. Krop, Donald A. Richards, Cristina Saura, Maura N. Dickler

Exposure to taselisib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b3143b00949194f3bf8e3da29e96f49
https://doi.org/10.1158/1078-0432.22470116

Zobrazit plný text záznamu

Supplementary Table S1. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Study disposition

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54688aa6bdc19b53f7e66ca2401b9476
https://doi.org/10.1158/1078-0432.22470125

Zobrazit plný text záznamu

Supplementary Table S3. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Adverse events (AEs) of special interest in the safety population

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ae6acd8abd9056f54efcd64e4886486
https://doi.org/10.1158/1078-0432.22470119

Zobrazit plný text záznamu

Supplementary Figure S1. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Participant PIK3CA-mutation central testing results

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2863ddcb43ff59658511ba8e4758454e
https://doi.org/10.1158/1078-0432.22470131.v1

Zobrazit plný text záznamu

Supplementary Table S5. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Clinical activity in patients with and without measurable disease at baseline

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f29410bfab495ae5608935e0bed6cca
https://doi.org/10.1158/1078-0432.22470113.v1

Zobrazit plný text záznamu

Supplementary Figure S2. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Time on treatment by taselisib dose and duration

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::746bc55763b1466342d2c810d4279f5b
https://doi.org/10.1158/1078-0432.22470128.v1

Zobrazit plný text záznamu

Supplementary Table S2. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Serious adverse events (SAEs) regardless of attribution in the safety population

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::899b1584587fb9b45f139d4eff2867e4
https://doi.org/10.1158/1078-0432.22470122.v1

Zobrazit plný text záznamu

Data from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Purpose: This single-arm, open-label phase II study evaluated the safety and efficacy of taselisib (GDC-0032) plus fulvestrant in postmenopausal women with locally advanced or metastatic HER2-negative, hormone receptor (HR)-positive breast cancer.Pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bcfa6f15e33353fab87b74f809dce14
https://doi.org/10.1158/1078-0432.c.6527435

Zobrazit plný text záznamu

Supplemental Methods from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Definition of adverse events of special interest (AESI)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cefcb97387728d98ee62316ec97bda0
https://doi.org/10.1158/1078-0432.22470134

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání